Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.

ABSTRACT:

Objective

Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases. PETRAM (NCT#:03405012) investigated whether BMD and bone turnover changes correlate.

Design

Open-label, randomized controlled trial.

Setting

Single-site, outpatient, secondary care.

Participants

Nonosteoporotic, virologically suppressed, cis-male PWH taking TDF/emtricitabine (FTC)/rilpivirine (RPV) for more than 24 weeks.

Intervention

Continuing TDF/FTC/RPV versus switching to TAF/FTC/RPV (1 : 1 randomization).

Main outcome measures

:[ 18 F]NaF-PET/CT for bone turnover (standardized uptake values, SUV mean ) and dual-energy x-ray absorptiometry for lumbar s

SUBMITTER: Moore AEB 

PROVIDER: S-EPMC10906193 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature